Gevorg Yaghjyan/LinkedIn
Apr 2, 2026, 15:52
Gevorg Yaghjyan: How Yale is Redefining Bladder Cancer Treatment Through Strategy Focused Trials
Gevorg Yaghjyan, Former Project Leader at Parexel, shared a post on LinkedIn:
“Clinical trials are evolving from testing drugs to testing strategies.
A new study from Yale School of Medicine in metastatic bladder cancer highlights this shift:
- Systemic therapy (ADC plus immunotherapy)
- Response-based patient selection
- Consolidative surgery in responders
This is not a traditional trial.
It’s a multimodal, adaptive treatment pathway.
From a clinical development perspective, key takeaways:
- Dynamic, response – driven enrollment
- Integration of medical plus surgical oncology
- Increasing operational complexity at site level
- Movement toward strategy – based endpoints
This is where oncology trials are heading:
From molecule-focused – to patient pathway – focused design”
Stay updated with Hemostasis Today.
-
May 20, 2026, 10:24How to Recognize Stroke Symptoms Instantly – Duke Health
-
May 20, 2026, 08:27Ahmed Koriesh: Persistent Delays, Higher Mortality, and Opportunities for Improvement for In-Hospital Stroke
-
May 20, 2026, 08:18ASH Launches Comprehensive Clinical Trial Learning Tool
-
May 20, 2026, 08:06Syed Mushahid Hussain: One of the Biggest Mistakes in CBC Interpretation is Analyzing Values in Isolation
-
May 20, 2026, 08:03Ann Marie O’Neill: Help Us Improve Information for DOAC Medicines
-
May 20, 2026, 08:03Tareq Abadl: Exploring the Clinical Power of Serum Protein Electrophoresis
-
May 20, 2026, 07:51Haroun Gajraj: Upto 30% of Patients Develop Brown Marks After Microsclerotherapy
-
May 20, 2026, 07:50Karen Schreiber: The BBQ Trial and the Challenge of Conducting Pregnancy RCTs
-
May 20, 2026, 07:49Dilini Christina Ranasinghe: Paediatric TPE Is Not Simply Adult TPE in a Smaller Patient